Short Interest in Pasithea Therapeutics Corp. (NASDAQ:KTTA) Expands By 37.2%

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 25,800 shares, an increase of 37.2% from the December 31st total of 18,800 shares. Currently, 2.5% of the company’s shares are short sold. Based on an average daily volume of 40,700 shares, the short-interest ratio is currently 0.6 days.

Pasithea Therapeutics Trading Down 1.6 %

NASDAQ KTTA opened at $2.48 on Thursday. Pasithea Therapeutics has a twelve month low of $2.20 and a twelve month high of $9.25. The stock has a fifty day simple moving average of $2.76 and a 200-day simple moving average of $3.91.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.